Healthcare is no longer just a once-a-year benefits renewal issue—it's becoming a CFO-grade risk that can disrupt forecasts, force trade-offs, and limit investment in wages, growth, and workforce transformation.
Emerging cost accelerants, especially pharmaceuticals, are a growing concern for CFOs.
47% of CFOs cited GLP-1 drugs as very concerning or significantly concerning because adoption can expand quickly, shift spend mid-year and materially change pharmacy cost with uncertain near-term offsets. GLP-1s may improve long-term health, but their rapidly rising costs can outpace budgets and planning.
Our new playbook brings together research and practical frameworks to help leaders understand what's driving cost pressure and take six strategic actions. Learn how to build a more active operating rhythm—with tighter monitoring, scenario modeling, and more frequent reforecasting— so you can manage people spend like a portfolio, reduce volatility, and protect the employee experience while avoiding downstream costs.